A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial.
Por:
Buisan O, Servian P, Pedreño-Lopez S, Pagès J, Urrea V, Martínez R, Garcia E, Cardona PJ, Vilaplana C, Amat M, Areal J, Bellmunt J, Clotet B and Cabrera C
Publicada:
1 feb 2026
Ahead of Print:
14 oct 2025
Resumen:
Intravesical bacillus Calmette-Guérin (BCG) is the standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC); however, recurrence and progression remain major challenges. To explore a heterologous prime-boost strategy, we conducted the RUTIVAC-1 trial (NCT03191578) to evaluate RUTI, a nonlive vaccine, derived from Mycobacterium tuberculosis, as a systemic primer prior to intravesical BCG in high-risk NMIBC patients. The immunogenicity, safety, and preliminary efficacy of RUTI was evaluated. In this phase 1, randomized, double-blind, placebo-controlled trial, 40 NMIBC patients were randomized 1:1 to receive two subcutaneous doses of RUTI (25 µg) or placebo before BCG treatment. Immunogenicity was assessed by flow cytometry, and clinical follow-up was extended to 5 yr. RUTI induced a systemic vaccine-specific response, increasing activation markers on CD4(+) and CD8(+) T cells, supporting effective immune priming. Regulatory T-cell expansion was observed in the placebo group but not in RUTI-vaccinated patients, who also exhibited a more heterogeneous and polyfunctional specific immune response. RUTI was safe and well tolerated, with only mild injection-site reactions. Exploratory analyses showed a trend toward reduced recurrence, progression, and death, with improved 5-yr progression-free survival. The small sample size and baseline imbalances were the limitations. This phase 1 study supports the safety and immunogenicity of RUTI and provides encouraging data that warrant confirmation in larger trials to establish its potential clinical benefit as a novel therapeutic strategy.
Filiaciones:
Buisan O:
Department of Urology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Department of Urology, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, Spain
:
Department of Urology, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, Spain
Pedreño-Lopez S:
IrsiCaixa, Badalona, Barcelona, Spain
:
Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
:
IrsiCaixa, Badalona, Barcelona, Spain
Martínez R:
Department of Urology, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, Spain
Department of Urology, Hospital Universitario Río Hortega, Valladolid, Spain
:
IrsiCaixa, Badalona, Barcelona, Spain
:
Microbiology Department, Northern Metropolitan Clinical Laboratory, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Unitat de Tuberculosi Experimental, Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Catalonia, Spain
Autonomous University of Barcelona, Bellaterra, Spain
:
Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
Autonomous University of Barcelona, Bellaterra, Spain
CIBER Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
High-Complexity Transversal Area in Tuberculosis, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Amat M:
Archivel Farma, Badalona, Barcelona, Spain
Areal J:
Department of Urology, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, Spain
Bellmunt J:
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
:
IrsiCaixa, Badalona, Barcelona, Spain
Infectious Diseases Department, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Universitat de Vic Central de Catalunya, Vic, Spain
:
IrsiCaixa, Badalona, Barcelona, Spain
Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
Autonomous University of Barcelona, Bellaterra, Spain
Green Submitted
|